Disc Medicine (IRON)
NASDAQ:IRON
Top Page
Disc Medicine
(NASDAQ:IRON)
Select Model
Select Model
Rating:43Neutral
Price Target:
$58.00
▼(-6.47% Downside)
Action:ReiteratedDate:02/28/26
The score is primarily constrained by accelerating losses and a sharp step-up in cash burn, with additional pressure from recent negative FDA/regulatory developments and restructuring. A comparatively strong, low-debt balance sheet is the key mitigating factor, while technicals and valuation remain unsupportive.
Positive Factors
Balance sheet strength & liquidity
Disc Medicine’s low debt and sizable equity base provide durable financial flexibility to fund multi-year clinical programs. A strong balance sheet reduces near-term refinancing risk, supports continued R&D investment, and preserves optionality to pursue partnerships or commercialization.
Negative Factors
Regulatory setback for lead asset
The FDA CRL raises the evidentiary bar for bitopertin, requiring Phase 3 APOLLO clinical endpoint data to demonstrate meaningful patient benefit. This materially delays potential approval, increases development cost and regulatory risk, and shifts the company’s timeline and commercialization assumptions.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength & liquidity
Disc Medicine’s low debt and sizable equity base provide durable financial flexibility to fund multi-year clinical programs. A strong balance sheet reduces near-term refinancing risk, supports continued R&D investment, and preserves optionality to pursue partnerships or commercialization.
Read all positive factors
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.29B
Dividend YieldN/A
Average Volume (3M)896.85K
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue GrowthN/A
EPS Growth-34.96%
CountryUS
Employees94
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.64
Shares Outstanding38,160,065
10 Day Avg. Volume618,592
30 Day Avg. Volume896,845
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.52K
Enterprise Value/Ebitda-10.64
Forecast
1Y Price Target
$99.60Price Target Upside60.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.86
Revenue Forecast (FY)$6.08M
Disc Medicine Business Overview & Revenue Model
Company Description
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates tha...
How the Company Makes Money
Disc Medicine is a clinical-stage biotechnology company and, based on publicly available information, does not have a broadly commercialized product portfolio generating recurring product sales. As a result, its revenue (when reported) is typicall...
Disc Medicine Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -281.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -207.94M | -108.27M | -76.23M | -47.39M | -30.90M |
| Net Income | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | |||||
| Total Assets | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | |||||
| Free Cash Flow | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Negative
62.01
Price Trends
68.07
Negative
77.17
Negative
70.03
Negative
Market Momentum
-2.15
Negative
42.82
Neutral
69.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Negative. The current price of 62.01 is above the 20-day moving average (MA) of 61.42, below the 50-day MA of 68.07, and below the 200-day MA of 70.03, indicating a bearish trend. The MACD of -2.15 indicates Negative momentum. The RSI at 42.82 is Neutral, neither overbought nor oversold. The STOCH value of 69.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRON.
Disc Medicine Risk Analysis
Disc Medicine disclosed 83 risk factors in its most recent earnings report. Disc Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Disc Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $2.63B | -228.91 | -10.26% | ― | 129.21% | 80.35% | |
62 Neutral | $2.82B | -51.51 | -19.63% | ― | 182.44% | 47.21% | |
52 Neutral | $1.72B | -3.82 | -31.07% | ― | 36.26% | -158.98% | |
52 Neutral | $1.55B | -2.84 | -63.98% | ― | -32.98% | -18.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.51B | -39.23 | -79.16% | ― | 114.22% | 77.02% | |
43 Neutral | $2.29B | -13.21 | -32.80% | ― | ― | -34.96% |
* Healthcare Sector Average
IRON
Disc Medicine
60.09
7.73
14.76%
AGIO
Agios Pharma
29.43
-0.85
-2.81%
TVTX
Travere Therapeutics
27.25
7.57
38.47%
ARQT
Arcutis Biotherapeutics
21.22
5.49
34.90%
TARS
Tarsus Pharmaceuticals
66.25
14.51
28.04%
RXRX
Recursion Pharmaceuticals
2.94
-2.87
-49.40%
Disc Medicine Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Disc Medicine Implements Restructuring Following FDA Response
Negative
Feb 27, 2026
On February 26, 2026, Disc Medicine, Inc.’s board approved a restructuring plan and management began implementation to better align its workforce with near-term strategic priorities after receiving a complete response letter from the U.S. Fo...
Business Operations and StrategyRegulatory Filings and Compliance
Disc Medicine Addresses FDA Rejection of Bitopertin Filing
Negative
Feb 17, 2026
Disc Medicine, Inc., a biopharmaceutical company developing therapies for hematologic diseases including rare conditions like erythropoietic protoporphyria, is advancing a pipeline led by bitopertin alongside other candidates such as DISC-0974 and...
Business Operations and StrategyRegulatory Filings and Compliance
Disc Medicine Receives FDA Complete Response on Bitopertin
Negative
Feb 13, 2026
Disc Medicine reported that on February 13, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for bitopertin as a treatment for erythropoietic protoporphyria, halting its bid for accelerated...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Disc Medicine prepares for potential 2026 bitopertin FDA decision
Positive
Jan 12, 2026
On January 12, 2026, Disc Medicine highlighted 2025 as a transformative year in which it submitted and secured priority review for a U.S. new drug application for bitopertin, received a Commissioner’s National Priority Review Voucher, report...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.